Ozempic and Semaglutide Cost: What You Pay in 2026

Regulatory noticeRegulatory note (verified August 22, 2026): On February 20, 2026 the FDA issued MEDVi, LLC a warning letter (MARCS-CMS 721455) citing misbranding under sections 502(a) and 502(bb) of the FD&C Act. Reviewing medvi.io in December 2025, the FDA said labels bearing "MEDVi" implied MEDVi compounds the drugs when it does not, and that "Same active ingredient as Wegovy and Ozempic" and "Same active ingredient as Mounjaro and Zepbound" implied an FDA approval compounded drugs do not have. We found no close-out letter, so the matter appears open. MEDVi states medvi.io is affiliate-operated rather than company-operated; we could not verify that, and the letter is addressed to MEDVi, LLC. Read the FDA letter

Regulatory noticeRegulatory note (verified August 22, 2026): The FDA reviewed struthealth.com in December 2025 and, on February 20, 2026, issued Strut Health, LLC a warning letter, MARCS-CMS 721448. It raises two separate problems. Pictured product labels carry the "Strut" name, which the agency said represents Strut as the compounder of the semaglutide and tirzepatide products when it is not. Three site claims are also quoted, among them "Generic Zepbound, Mounjaro" and "Semaglutide is the active ingredient in the brand medications." Because compounded drugs hold no FDA approval, the FDA said wording of that kind implies one, and it cited misbranding under sections 502(a) and 502(bb) of the FD&C Act. FDA’s warning letter index shows no response letter and no close-out letter, so we treat the matter as open. Read the FDA letter

Regulatory noticeRegulatory note (verified August 22, 2026): Eden Health International Inc. was sent FDA warning letter MARCS-CMS 728279 on June 8, 2026, following an agency review of tryeden.com in March 2026. The letter lists two findings. The first is the "Eden" name on pictured labels for compounded semaglutide and tirzepatide, which the FDA said represents Eden as the compounder when it is not. The second is the site’s description of its sourcing as "FDA-licensed 503(a) outsourcing facilities," a designation the agency says does not exist, because the FD&C Act creates no FDA approval or license for pharmacies or outsourcing facilities. Both were cited as misbranding under sections 502(a) and 502(bb). FDA has posted no close-out letter, so the matter reads as open. Read the FDA letter

Verification limitationVerification note (checked August 23, 2026): we could not identify the legal entity behind HealthRx through public records. Its website does not name an operating company, its domain registration is privacy-shielded, and we could not confirm a listing in any business registry or accreditation database we checked. This is not a finding of wrongdoing. It means our usual checks, including our search of FDA enforcement records, could only be run against the brand name and domain rather than a confirmed company.

Regulatory noticeRegulatory note (verified August 22, 2026): One sentence is all that FDA warning letter MARCS-CMS 715879 quotes. Sent to Sprout Health Partners LLC on September 9, 2025 after an August 2025 review of joinsprouthealth.com, it cites the line "GLP-1 medications are FDA-approved and backed by extensive clinical research..." Appearing on pages offering compounded semaglutide and tirzepatide, that statement implied to the agency that the compounded products themselves are FDA-approved, which they are not, and it was cited as misbranding under FD&C Act 502(a) and 502(bb). A search of FDA’s warning letter index turns up no close-out letter, so the matter appears open. Read the FDA letter

Regulatory noticeRegulatory note (verified August 22, 2026): Skinny.Rx operates as SkinnyRx, but the legal entity is Lean Rx, Inc., and that is the name on FDA warning letter MARCS-CMS 717989, dated February 20, 2026. Following a December 2025 review of skinnyrx.com, the agency objected to the "SkinnyRx" name on pictured labels, saying it implies SkinnyRx compounds the drugs itself, and to three marketing lines, including "Get access to the same active ingredient as name-brand GLP-1 medications" and "It contains the same active ingredient as FDA-approved medications." Compounded semaglutide and tirzepatide are not FDA-approved, so the FDA read those lines as implying an approval that does not exist and classed the products as misbranded. No close-out letter is posted; read the matter as unresolved. Read the FDA letter

Regulatory noticeRegulatory note (verified August 22, 2026): Hers is a brand of Hims & Hers Health, Inc., and the FDA wrote to that company twice on September 9, 2025, once for each brand. The Hers letter, MARCS-CMS 716825, went to chief executive Andrew Dudum after an August 2025 review of forhers.com. It quotes two claims made for compounded semaglutide: "Weekly injectable GLP-1 with the same active ingredient as Ozempic and Wegovy" and "Clinically proven ingredients." The agency’s position is that compounded products carry no FDA approval, so claims like these imply a sameness with approved medicines that has not been established, making the products misbranded. FDA’s index lists neither a response nor a close-out letter, so the matter stands open. Read the FDA letter

Regulatory noticeRegulatory note (verified August 22, 2026): On September 9, 2025 the FDA sent Hims & Hers Health, Inc. a warning letter covering the Hims brand, MARCS-CMS 716567, drawn from a review of hims.com the previous month. Two lines about compounded semaglutide are quoted in it: "Same active ingredient as Ozempic and Wegovy" and "Clinically proven ingredients." Compounded drug products are not FDA-approved, and the agency said phrasing of this sort suggests otherwise, which is what makes the products misbranded under FD&C Act sections 502(a) and 502(bb). A companion letter went to the same company that day for its Hers brand. No close-out letter appears in FDA’s index; treat this as open. Read the FDA letter